3 results
Objectives of part A:- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after 5 days of dosing in people with Parkinson's disease- evaluate the safety, tolerability and pharmacokinetics of 2, 3 or 4 mg AZ-009 after…
This study aims to assess the Pharmacokinetic (PK)-parameters and safety of treatment with BR-003 in humans. BR-003 is a pliable, ring-shaped, biocompatible hydrogel that contains bupivacaine, a well-known and approved local anaesthetic. Attached to…
To prospectively investigate if a treatment strategy in which two types of cytotoxic RLT, i.e., an alpha-emitter and a beta-emitter, are alternatively offered to patients with oligometastatic HSPCa, is feasible and safe